Literature DB >> 12204534

Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.

Heather L Maecker1, Zhong Yun, Holden T Maecker, Amato J Giaccia.   

Abstract

Epigenetic regulation of gene expression significantly influences cell growth and differentiation. Here we show that epigenetic silencing of Fas determines tumor growth in vivo and apoptotic sensitivity in vitro. In established tumors with epigenetically repressed Fas, restoration of Fas activity either by transfection of fas or treatment with Trichostatin A (TSA), an inhibitor of histone deacetylase, suppresses tumor growth and restores chemosensitivity. The TSA-dependent chemosensitivity and tumor growth control require both tumor Fas and the host NK (natural killer) cell functions. This work demonstrates the importance of epigenetic modification of Fas in tumor progression and immune evasion, and emphasizes the essential interplay between Fas and innate immunity in the control of chemoresistant tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204534     DOI: 10.1016/s1535-6108(02)00095-8

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  27 in total

1.  Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis.

Authors:  Vladimir N Ivanov; Ze'ev Ronai; Tom K Hei
Journal:  J Biol Chem       Date:  2005-11-23       Impact factor: 5.157

2.  FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.

Authors:  Janet K Horton; Sharareh Siamakpour-Reihani; Chen-Ting Lee; Ying Zhou; Wei Chen; Joseph Geradts; Diane R Fels; Peter Hoang; Kathleen A Ashcraft; Jeff Groth; Hsiu-Ni Kung; Mark W Dewhirst; Jen-Tsan A Chi
Journal:  Radiat Res       Date:  2015-10-21       Impact factor: 2.841

3.  Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.

Authors:  Chris Z Y Zhang; George G Chen; Juanita L Merchant; Paul B S Lai
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

4.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.

Authors:  Amine Achachi; Arnaud Florins; Nicolas Gillet; Christophe Debacq; Patrice Urbain; Germain Manfouo Foutsop; Fabian Vandermeers; Agnieszka Jasik; Michal Reichert; Pierre Kerkhofs; Laurence Lagneaux; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

5.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

Authors:  J Sträter; U Hinz; C Hasel; U Bhanot; G Mechtersheimer; T Lehnert; P Möller
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 6.  Combining epigenetic and immune therapy to overcome cancer resistance.

Authors:  Stephanie Gomez; Tomasz Tabernacki; Julie Kobyra; Paige Roberts; Katherine B Chiappinelli
Journal:  Semin Cancer Biol       Date:  2019-12-23       Impact factor: 15.707

7.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

8.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

9.  siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli.

Authors:  Richard Tritz; Barbara M Mueller; Michelle J Hickey; Amy H Lin; German G Gomez; Philipp Hadwiger; Dinah W Y Sah; Leslie Muldoon; Edward A Neuwelt; Carol A Kruse
Journal:  Cancer Ther       Date:  2008

Review 10.  Targeting cell death in tumors by activating caspases.

Authors:  Sarah H MacKenzie; A Clay Clark
Journal:  Curr Cancer Drug Targets       Date:  2008-03       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.